文献速递血液净化与透析

成熟动静脉内瘘狭窄以收缩型平滑肌细胞和versican为特征

Stenosis in Mature Arteriovenous Fistulas Characterized by Contractile Smooth Muscle Cells and Versican.
PubMed 文献 · Kidney Int Rep · 2026-07-28

INTRODUCTION: Stenosis occurs in 20% to 40% of mature arteriovenous fistulas (AVFs). Alterations of the vessel wall composition in stenosis should provide insights into its pathogenesis.…

要点

  • 成熟AVF狭窄壁以胶原和蛋白聚糖重塑为主,vSMC呈收缩型表型
  • 狭窄处versican与versikine表达升高且两者线性相关
  • 增殖细胞位于距内皮下>50至100微米处,提示狭窄形成存在时间连续过程

核心结论

  • 成熟AVF的晚期狭窄以收缩型vSMC表型和细胞外蛋白聚糖丰富的重塑为特征。
  • AVF狭窄病变可能是时间连续过程:vSMC先呈合成和/或增殖表型,狭窄稳定后转为收缩表型。

研究设计与样本

  • 研究使用21例AVF外植物,采用定制机器学习方法定量细胞成分(vSMC)和非细胞成分(胶原和细胞外基质)。

主要发现

  • AVF壁中蛋白聚糖和胶原多于vSMC,并沿针道出现破坏。
  • 狭窄壁显示致密胶原排列,perlecan、versican和versikine表达更高,且versican与versikine呈线性相关。
  • 狭窄处vSMC的MYH11、Calponin和smooth muscle actin(收缩和/或静息标志物)高于Ki67(增殖标志物),osteopontin(分泌标志物)未增加。
  • 增殖细胞位于距内皮下>50至100微米处。

临床怎么用

  • 病理评估成熟AVF狭窄时应关注vSMC表型(收缩型标志物MYH11、Calponin、SMA)及versican/versikine表达。
  • 该研究提示AVF狭窄存在异质性,靶向治疗需针对特定成分,但尚需更深入理解成熟AVF狭窄生物学。

局限性

  • 样本量有限(21例AVF外植物),且为外植物研究,可能无法完全反映在体狭窄动态过程。
  • 研究为描述性观察,未提供治疗干预数据,紫杉醇涂层器械反应异质性的机制仅为推测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stenosis occurs in 20% to 40% of mature arteriovenous fistulas (AVFs). Alterations of the vessel wall composition in stenosis should provide insights into its pathogenesis. However, there is a dearth of studies examining the vessel wall composition of AVF with secondary failure. METHODS: Twenty-one AVF explants were used. Cellular (vascular smooth muscle cells [vSMCs]) and noncellular components (collagen and extracellular matrix [ECM]) were quantified using a customized machine-learning approach. RESULTS: AVFs were explanted for aneurysms (16/21), pseudoaneurysms (2/21), or cosmetic reasons (3/21). Fifteen of the AVFs had a stenotic lesion. Proteoglycans and collagen predominated over vSMCs in the AVF wall and showed disruptions along the needle tracks. The stenotic wall showed compact collagen organization and higher expression of perlecan, versican, and versikine, and a linear correlation between versican and versikine. vSMCs in stenosis showed higher myosin heavy chain 11 (MYH11), Calponin, and smooth muscle actin (contractile and/or quiescent markers) than Ki67, a proliferative marker, without an increase in osteopontin (a secretory marker). Proliferating cells were located > 50 to 100 microns from the subendothelium. CONCLUSION: Advanced stenosis in mature AVFs are characterized by contractile vSMC phenotype and predominated by extracellular and proteoglycan-rich remodeling raising a possibility of AVF stenotic lesions as a temporal continuum in which vSMCs initially adopt a synthetic and/or proliferative phenotype during stenosis formation and subsequently contractile phenotype as the stenosis stabilizes. Although providing potential insights into the heterogeneous response of paclitaxel-coated devices in AVF stenosis, this study underscores the need for a deeper understanding of the biology of stenosis in mature AVFs and the use of targeted therapies for specific components in AVF stenosis.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Elzinad N, Lotfollahzadeh S, et al. Stenosis in Mature Arteriovenous Fistulas Characterized by Contractile Smooth Muscle Cells and Versican. Kidney Int Rep. 2026. PMID: 42662145. doi:10.1016/j.ekir.2026.106997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。